GlassScriptPhysician profile
Alexandra Vlad
NPI 1710447917
$1,084.54
in general payments reported to CMS, 2019-2025
14 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.01 · 2021: $54.22 · 2022: $418 · 2023: $174 · 2024: $254 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $372.25 | 2022-2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $166.37 | 2024-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $149.36 | 2021-2025 | Zerbaxa, Recarbrio, Dificid |
| Calliditas Therapeutics US INC. | $100.32 | 2022-2024 | Tarpeyo |
| Alcon Vision LLC | $62.88 | 2024 | Clareon |
| Novartis Pharmaceuticals Corporation | $59.48 | 2020-2021 | |
| Horizon Therapeutics Plc | $53.25 | 2023 | Tepezza |
| Abbvie INC. | $26.43 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.66 | 2023 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.83 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.22 | 2022 | |
| Melinta Therapeutics, LLC | $13.55 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Vlad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.